18 F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging

Abstract

Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with 68 Ga-labeled compounds has rapidly become adopted as part of routine clinical care in many parts of the world.However, recent years have witnessed the start of a shift from 68 Ga-to 18 F-labeled PSMA-targeted compounds.The latter imaging agents have several key advantages, which may lay the groundwork for an even more widespread adoption into the clinic.First, facilitated delivery from distant suppliers expands the availability of PET radiopharmaceuticals in smaller hospitals operating a PET center but lacking the patient volume to justify an onsite 68 Ge/ 68 Ga generator.Thus, such an approach meets the increasing demand for PSMA-targeted PET imaging in areas with lower population density and may even lead to cost-savings compared to in-house production.Moreover, 18 F-labeled radiotracers have a higher positron yield and lower positron energy, which in turn decreases image noise, improves contrast resolution, and maximizes the likelihood of detecting subtle lesions.In addition, the longer half-life of 110 min allows for improved delayed imaging protocols and flexibility in study design, which may further increase diagnostic accuracy.Moreover, such compounds can be distributed to sites which are not allowed to produce radiotracers on-site due to regulatory issues or to centers without access to a cyclotron.In light of these advantageous characteristics, 18 F-labeled PSMA-targeted PET radiotracers may play an important role in both optimizing this transformative imaging modality and making it widely available.We have aimed to provide a concise overview of emerging 18 F-labeled PSMA-targeted radiotracers undergoing active clinical development.Given the wide array of available radiotracers, comparative studies are needed to firmly establish the role of the available 18 F-labeled compounds in the field of molecular PCa imaging, preferably in different clinical scenarios.

References 109

1. 1.

   Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016;19:395-7.

   Not in our library10.1038/pcan.2016.30

2. 2.

   Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.

   Not in our library10.3322/caac.21442

3. 3.

   Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46:3040-52.

   Not in our library10.1016/j.ejca.2010.09.013

4. 4.

   Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016;70:926-37.

   Not in our library10.1016/j.eururo.2016.06.021

5. 5.

   PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Mol Imaging Biol. 2016;18:411-9.

   Not in our library10.1007/s11307-016-0957-6

6. 6.

   (68)Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging. 2019;46:31-9.

   Not in our library10.1007/s00259-018-4189-7

7. 7.

   German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2017;58:85-90.

   Not in our library10.2967/jnumed.116.183194

8. 8.

   Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125-35.

   Not in our library10.1056/nejmoa1607427

9. 9.

   The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics. 2018;8:6088-100.

   Not in our library10.7150/thno.30357

10. 10.
    225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study · 2018

    Corrected
11. 11.

    Theranostic Concepts: More Than Just a Fashion Trend-Introduction and Overview. J Nucl Med. 2017;58:1S-2S.

    Not in our library10.2967/jnumed.117.199570

12. 12.

    [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825-33.

    Not in our library10.1016/s1470-2045(18)30198-0

13. 13.

    PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics. 2015;5:1388-401.

    Not in our library10.7150/thno.13348

14. 14.

    Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015;17:565-74.

    Not in our library10.1007/s11307-015-0850-8

15. 15.

    Moving into the next era of PET myocardial perfusion imaging: introduction of novel (18)F-labeled tracers. 2018.

    Not in our library10.1007/s10554-018-1469-z

16. 16.

    Recent paradigm shifts in molecular cardiac imaging-Establishing precision cardiology through novel (18)F-labeled PET radiotracers. 2019.

    Not in our library10.1016/j.tcm.2019.02.007

17. 17.

    Practical Aspects of 18F-FDG PET When Receiving 18F-FDG from a Distant Supplier. J Nucl Med Technol. 2009;37:164-9.

    Not in our library10.2967/jnmt.109.062950

18. 18.
    Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer · 2015

    No notice
19. 19.

    PSA-Stratified Performance of (18)F- and (68)Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med. 2017;58:947-52.

    Not in our library10.2967/jnumed.116.185538

20. 20.

    Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution. Cancer Imaging. 2019;19:23.

    Not in our library10.1186/s40644-019-0211-y

21. 21.

    2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645-53.

    Not in our library10.1158/1078-0432.ccr-11-1357

22. 22.

    18F-Labeled Peptides: The Future Is Bright. Molecules. 2014;19:20536-56.

    Not in our library10.3390/molecules191220536

23. 23.

    Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjug Chem. 2015;26:1-18.

    Not in our library10.1021/bc500475e

24. 24.

    Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883-91.

    Not in our library10.2967/jnumed.112.104661

25. 25.

    (1)(8)F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. J Nucl Med. 2015;56:1003-10.

    Not in our library10.2967/jnumed.115.154336

26. 26.

    Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naive and Castration-Resistant Metastatic Prostate Cancer. J Nucl Med. 2016;57:46-53.

    Not in our library10.2967/jnumed.115.163782

27. 27.

    18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology. Clin Nucl Med. 2017;42:735-40.

    Not in our library10.1097/rlu.0000000000001804

28. 28.

    Clinical impact of PSMA-based (18)F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. Eur J Nucl Med Mol Imaging. 2018;45:4-11.

    Not in our library10.1007/s00259-017-3818-x

29. 29.

    Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:89-101.

    Not in our library10.1007/s00259-013-2527-3

30. 30.

    BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study). Mol Imaging Biol. 2015;17:424-33.

    Not in our library10.1007/s11307-014-0800-x

31. 31.
    F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients · 2016

    No notice
32. 32.

    First-in-Human Phase I study of CTT1057, a Novel (18)F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer. 2018.

    Not in our library10.2967/jnumed.118.220715

33. 33.

    Initial evaluation of PET/CT with (18) F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients. Cancer Sci. 2019;110:742-50.

    Not in our library10.1111/cas.13911

34. 34.

    Discovery of (18)F-JK-PSMA-7, a novel PET-probe for the detection of small PSMA positive lesions. 2018.

    Not in our library10.2967/jnumed.118.218495

35. 35.

    In vitro and in vivo characterization of a 18F-AlF-labeled PSMA ligand for imaging of PSMA-expressing xenografts. J Nucl Med. 2019;60:1017-22.

    Not in our library10.2967/jnumed.118.218941

36. 36.

    Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. J Nucl Med. 2016;57:90S-6S.

    Not in our library10.2967/jnumed.115.170175

37. 37.

    Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55-62.

    Not in our library10.1016/j.apradiso.2012.06.034

38. 38.

    Physical performance comparison of Ga-68 and F-18 in small animal PET system. J Nucl Med. 2010;51:1423.

    Not in our library

39. 39.

    Gallium-68 EDTA PET/CT for Renal Imaging. Semin Nucl Med. 2016;46:448-61.

    Not in our library10.1053/j.semnuclmed.2016.04.002

40. 40.

    Editorial commentary: Potential for personalized imaging with new radiotracers and cardiac PET. 2019.

    Not in our library10.1016/j.tcm.2019.04.010

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.